An innovative bedside genetic test being implemented in Manchester could dramatically improve outcomes for thousands of people in the UK affected by stroke each year.

Developed by researchers from Manchester University NHS Foundation Trust (MFT) and The University of Manchester, in collaboration with Manchester based company genedrive, the test can tell healthcare professionals in approximately one hour if stroke patients will be more likely to benefit from clopidogrel, the current first-line treatment to prevent recurrence.

Using a simple cheek swab, the non-invasive test can be performed at the bedside. From the swab, the genedrive system interprets the genetic information on the patient and informs the clinician with options on the course of treatment.

Previously, genetic testing for CYP2C19 could only be carried out using specialist laboratories, a process which can take several days.

The innovative test was used successfully at Manchester Royal Infirmary and the Manchester Centre for Genomic Medicine, Saint Mary’s Hospital, both part of MFT, over six months, to evaluate performance in the clinical setting.

Further testing will be carried out at Greater Manchester’s Hyper Acute Stroke Unit (HASU) at Salford Royal Hospital, part of Northern Care Alliance NHS Foundation Trust, to establish the benefit for patients across Greater Manchester. HASU is the largest dedicated unit in the region and provides care for people across Greater Manchester. This work is part supported by our Centre through the Edward and Victoria Bonham Carter fund and NHS England Network of Excellence in Pharmacogenetics and Medicines Optimisation.

This pilot is an important step in understanding the set-up costs, workforce and other requirements to roll out this innovation wider.

Read more on here. 

Related